Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection

Summary

The primary objectives are to assess the antiviral activity, clinical safety and tolerability parameters of albuvirtide/3BNC117 combination therapy in reducing HIV-1 viral load during the 1-week induction period treatment period.

Timeline

Start

2021-11-30

Primary completion

2022-11-01

Completion

2022-12-01

Outcome

Met primary endpoint

paper By day 14, 62.5% showed a ≥ 0.5 log10 reduction from day 7 (p = 0.012 vs. control), with a mean drop of 1.05 log10. PMID 41896772 ↗

Publications

• Zhou Y, Qin Y, Liu X, Zhao Q, Wang M, Chen Y, Li Y, He K, Li X, Harypursat V, Xie D, Chen Y. Albuvirtide plus 3BNC117 provides a promising combination strategy for multidrug-resistant HIV-1 infection: a prospective, open-label, multicenter phase 2 trial. BMC Infect Dis. 2026 Mar 28;26(1):911. doi: 10.1186/s12879-026-12987-3.

Drugs

Indications